Turning single-cell clarity into cancer therapeutic opportunity through AI, WittGen develops a Single-Cell Cancer Drug Discovery Gen AI/ML Accelerator, LEIBER-X that boosts novel target/biomarker discovery, MoA monitoring and patient stratification, ensuring new drug success at cellular-level resolution. Our platform provides tailored companion diagnostics to optimize cancer treatment outcomes. Make Every Cell Counts!
Company Details
- Employees
- 6
- Founded
- -
- Address
- Berkeley, California 94704, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.wittgenbio.com
- Keywords
- machine learning, bioinformatics, cancer genomics, single cell RNA sequencing data analysis, downstream analysis automation, caner heterogeneity identification, Gen AI, Generative AI, Spatial Transcriptomics, cell subtype, Target ID, Target Priotization, MoA, MoA monitoring, single-cell, scRNA-seq, TME, Intra-tumor heterogeneity, precision oncology, biomarker, novel biomarker, unseen biomarker, IHC, Immunohisotchemistry, bulk RNA-seq, bulk, Deconvolution, pathway, phenotyping, companion, companion Dx, companion diagnostics, CDx, dosage, insilico, predicion, accuracy, celluar, high resolution, multi-omics, long-read.
- HQ
- Berkeley, California
Wittgen Biotechnologies Questions
Wittgen Biotechnologies's website is http://www.wittgenbio.com
Wittgen Biotechnologies's LinkedIn profile is https://www.linkedin.com/company/wittgen-biotechnologies
Wittgen Biotechnologies has
6 employees.
View email and phone details for 6
employees at Wittgen Biotechnologies.
Wittgen Biotechnologies's industry is
Biotechnology Research
Wittgen Biotechnologies's top competitors are
Benchlab Solutions,
Atlas Biotech,
Samsung Sds,
Meta,
Centers For Educational Equity And Excellence (Ce3),
Imideology,
Tma Precision Health,
42genetics,
(주)엘앤씨바이오 (Lncbio),
Hopeai.
Wittgen Biotechnologies's categories are Biotechnology Research
Wittgen Biotechnologies's founding year is 2023
